End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
148.9 INR | -3.22% | -5.61% | -14.03% |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2023 |
---|---|
Net sales 1 | 5,009 |
EBITDA 1 | 523.8 |
EBIT 1 | 502.9 |
Operating Margin | 10.04% |
Earnings before Tax (EBT) 1 | 572 |
Net income 1 | 435 |
Net margin | 8.68% |
EPS 2 | 13.36 |
Free Cash Flow 1 | 213.8 |
FCF margin | 4.27% |
FCF Conversion (EBITDA) | 40.81% |
FCF Conversion (Net income) | 49.15% |
Dividend per Share | - |
Announcement Date | 6/8/23 |
Balance Sheet Analysis
Fiscal Period: March | 2023 |
---|---|
Net Debt 1 | 249 |
Net Cash position 1 | - |
Leverage (Debt/EBITDA) | 0.4745 x |
Free Cash Flow 1 | 214 |
ROE (net income / shareholders' equity) | 50.6% |
ROA (Net income/ Total Assets) | 16.2% |
Assets 1 | 2,680 |
Book Value Per Share 2 | 30.90 |
Cash Flow per Share 2 | 0.3900 |
Capex 1 | 565 |
Capex / Sales | 11.28% |
Announcement Date | 6/8/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-14.03% | 76.15M | |
+17.73% | 66.69B | |
+16.33% | 41.24B | |
+19.11% | 25.89B | |
+12.78% | 19.81B | |
+0.85% | 17.48B | |
-21.87% | 15.86B | |
+2.32% | 15.35B | |
-10.29% | 15.23B | |
-22.30% | 13.36B |
- Stock Market
- Equities
- VALIANTLAB Stock
- Financials Valiant Laboratories Limited